{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-23-000019","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.352166+00:00","generated_at":"2026-06-16T08:54:33.359734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance","bullets":["Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).","Immunology portfolio $5.587B (-9%); Humira $3.541B (-25.2%), Skyrizi $1.360B (+44.7%), Rinvoq $686M (+47.5%).","Hematologic oncology $1.416B (-14%); Imbruvica $878M (-25.2%), Venclexta $538M (+13.7%).","Raises FY 2023 adj. diluted EPS guidance from $10.62-$11.02 to $10.72-$11.12.","Neuroscience $1.695B (+13.9%); aesthetics $1.300B (-5.4%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-23-000019","json":"https://secwatch.observer/filing/0001551152-23-000019.json","markdown":"https://secwatch.observer/filing/0001551152-23-000019.md","text":"https://secwatch.observer/filing/0001551152-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/0001551152-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/abbv-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:54:33.359734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cf8f629c5e170dcf41210aae96db8075aced7e7","claim":"AbbVie Inc. reported the first quarter ended March 31, 2023 results: revenue $12.225 Billion, EPS $0.13. Guidance raised.","evidence_excerpt":"AbbVie Reports First-Quarter 2023 Financial Results • Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.225 Billion, a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational Basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/0001551152-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$12.225 Billion"},{"label":"EPS","value":"$0.13"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}